Nurexone Biologic Inc. has released further results from a preclinical study of Exopten demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.
Lift Biosciences Ltd. has released preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities that could signal its potential to cure solid tumors. IMANp is generated from the hematopoietic stem cells of donors with exceptional anticancer innate immunity.
For COVID-19, the limited durability of vaccines requires multiple injections, and their effectiveness is continuously challenged by emerging new spike variants of the virus. The SARS-CoV-2 main protease Mpro plays a role in major polyprotein processing events and is essential for viral replication.
Gut bacteria used liquid-liquid phase separation (LLPS) to organize themselves into condensates, which allowed them to adapt to nutrient deprivation, enabling them to colonize the gut. In experiments reported in the March 17, 2023, issue of Science, investigators showed that a mutant of the beneficial gut bacterium Bacteroides thetaiotaomicron was “highly defective in competitiveness, in its ability to colonize the mammalian gut,” senior author Eduardo Groisman told BioWorld. “Our paper provides the first example in which [LLPS] matters in bacterial host interactions.”
Impact Therapeutics (Shanghai) Inc. has divulged substituted tricyclic compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors reported to be useful for the treatment of cancer.
Biofront Ltd. has described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) targeting moiety via linker acting as HPK1 degradation inducers reported to be useful for the treatment of cancer.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified dual antagonists of endothelin ETA receptor and angiotensin AT1 receptor reported to be useful for the treatment of diabetes, hypertension and renal disorders.
Reistone Biopharma Co. Ltd. has synthesized quinolinofuran derivatives acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the treatment of fibrosis, autoimmune, inflammatory and metabolic disorders.
The neuron-specific K+/Cl- co-transporter KCC2 is involved in the shift from depolarizing to hyperpolarizing γ-aminobutyric acid receptor (GABAAR) currents and subsequent synaptic inhibition.
RSS
